BOTHELL, Wash., Dec. 23, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues  ("BioLife" or the "Company"), today announced that pharmaceutical industry cold chain expert Kevin O'Donnell has joined the Company as Vice President, Cold Chain Standards, Practices & Compliance.

Most recently Kevin was a Senior Partner at Exelsius Cold Chain Management Consultancy, working at high levels within industry, international organizations, government agencies, and academia, to shape and improve the quality of healthcare product delivery through comprehensive good supply chain practices.  In this role he provided consulting, research and training services to drug manufacturers, airlines, freight forwarders, supply chain goods and services providers and other stakeholders in the life science logistics sector.  

Mike Rice, BioLife President & CEO, stated, "I am delighted that Kevin has joined our team and look forward to the immediate and many contributions he will make as we continue to fine tune our biologistex cold chain management service offering, which uses the SAVSU EVO smart container for transportation and tracking of temperature sensitive biologic materials throughout the delivery chain."

Kevin is recognized internationally as a key opinion leader focused on the development, promotion and implementation of industry best practices. He was awarded "Temperature Controlled Logistics Leader for 2012" by IQPC's Temperature Control Logistics & Quality Network, an international industry peer group recognizing 15 of the most influential and inspiring thought leaders in global pharmaceutical supply chain.

Kevin is also an elected member of the United States Pharmacopeia Convention Expert Committee for Packaging, Storage and Distribution and a recipient of the 2013 USP Award for Innovative Response to Public Health Challenges for outstanding work and leadership. He's a Temporary Advisor to the World Health Organization, a Certified Facilitator for the WHO/PDA Pharmaceutical Cold Chain Management on Wheels Course, and their ePELA Authentic e-Learning Course on Pharmaceutical Cold Chain Management.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol^® and CryoStor^® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This press release contains forward-looking statements, including, but not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new products, and third party projections regarding the future market for regenerative medicine and cold chain packaging and instrumentation services. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; reliance upon SAVSU for completing the development and manufacturing of biologistex CCM's products; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations
Daphne Taylor
Senior Vice President, Chief Financial Officer
(425) 402-1400
dtaylor@biolifesolutions.com

SOURCE BioLife Solutions, Inc.